This lecture provides a comprehensive overview of the molecular pathology workflow, designed for surgical pathologists. The presentation follows the journey of a tissue specimen, beginning with critical pre-analytic factors such as fixation methods, contaminants, and the crucial concept of tumor cellularity, which dictates assay sensitivity. It then details the five main steps of nucleic acid extraction—lysis, cleanup, purification, washing, and elution—along with essential quality control measures to assess the purity, quantity, and integrity of the extracted material. The core of the lecture contrasts foundational techniques like PCR and Sanger sequencing with the more advanced Next-Generation Sequencing (NGS). A significant focus is placed on comparing the two primary NGS methodologies: amplicon-based (e.g., Ion Torrent) and hybrid capture-based (e.g., Illumina). The speaker elaborates on their distinct mechanisms for target enrichment, amplification, and sequencing chemistry, highlighting their respective advantages and limitations, such as the amplicon-based approach's difficulty with homopolymers and the hybrid capture method's strength in detecting novel gene fusions. The utility of RNA sequencing for fusion and splice variant analysis is also explained. Clinical case studies are used throughout to illustrate how these technical considerations directly impact diagnostic outcomes.
A Pathologist's Guide to the Molecular Lab Workflow
0:05:13 Specimen Selection is Critical: The journey begins with the specimen. Key pre-analytic factors that impact the quality of nucleic acid include cold ischemic time, the type of fixative used (neutral buffered formalin is good; acidic decalcifying solutions are bad as they fragment DNA), and contaminants like mucin or necrosis.
0:07:38 Understanding Tumor Cellularity: This is a critical metric, defined as the percentage of tumor nuclei relative to the total number of nuclei in a given area. Most molecular assays have a minimum cellularity requirement (e.g., 20-30%) to ensure that a potential mutation can be detected above the assay's noise threshold.
0:10:45 Enriching for Tumor Cells: To meet cellularity requirements, labs use enrichment techniques. These range from simply scraping unstained slides (macro-dissection) to using a microscope to precisely select tumor areas (micro-dissection), thereby removing non-tumor tissue like stroma or lymphocytes that would dilute the tumor DNA.
0:12:44 Case Study: The Impact of Low Cellularity: A case of metastatic appendiceal adenocarcinoma with high mucin content and low cellularity showed a KRAS mutation at a very low allele frequency (2%), below the official 5% limit of detection. The lab decided to report it with a comment, as the low frequency was consistent with the poor specimen quality, providing crucial information to the clinician.
0:18:08 The Nucleic Acid Extraction Process: Once a sample is selected, nucleic acid is extracted in five steps: 1) Lysis (breaking open cells), 2) Cleanup (removing cellular debris), 3) Purification (isolating nucleic acids, often with spin columns or magnetic beads), 4) Washing (removing contaminants), and 5) Elution (releasing pure nucleic acid into a solution).
0:26:53 PCR and Sanger Sequencing Basics: Polymerase Chain Reaction (PCR) is a foundational technique used to exponentially amplify a specific DNA target. Sanger sequencing then determines the exact base sequence of that amplified product. Key Takeaway: Sanger sequencing has a low sensitivity, requiring a mutation to be present in at least 20% of the DNA copies (20% allele frequency) to be reliably detected.
0:38:45 Introduction to Next-Generation Sequencing (NGS): Also called massively parallel sequencing, NGS allows for the simultaneous sequencing of millions of DNA fragments. This high-throughput capability gives it far greater sensitivity than Sanger sequencing and the ability to analyze many genes at once.
0:41:01 Key NGS Approaches: Amplicon vs. Hybrid Capture: There are two main strategies for targeting genes in NGS:
Amplicon-based (e.g., Ion Torrent): Uses highly specific PCR primers to amplify many targets at once. It's fast, cost-effective, and requires little input DNA. However, it can miss mutations if they occur where a primer needs to bind (allele dropout) and cannot identify unknown gene fusion partners.
Hybrid Capture-based (e.g., Illumina): Uses synthetic DNA probes to bind to and "capture" genes of interest from the entire sample. It requires more DNA and is slower but is better at uniform coverage and can identify novel fusion partners because it captures the entire gene region.
0:47:05 Different Sequencing Chemistries: Ion Torrent technology detects the release of hydrogen ions (a pH change) as DNA bases are incorporated, which can be inaccurate when reading long stretches of the same base (homopolymers). Illumina technology uses fluorescently-labeled bases and takes a picture after each one is added, which is generally more accurate.
0:55:29 Why Use RNA Sequencing? While most sequencing is done on DNA, RNA sequencing is superior for detecting gene fusions. This is because fusion breakpoints often occur in large, difficult-to-sequence intron regions of DNA. RNA sequencing analyzes the final spliced messenger RNA (mRNA), which only contains the exons, making the fusion junction much easier to identify.
1:01:38 Targeted vs. Unbiased Platforms: Clinical labs typically use targeted panels that sequence a specific set of clinically relevant genes. In contrast, unbiased approaches like Whole Exome or Whole Genome Sequencing analyze all genes and are primarily used in research or for complex cases with no clear diagnosis.